

## **Cell and Gene Therapy Tools, and Reagents: Global Markets**

Market Research Report | 2024-11-07 | 136 pages | BCC Research

### **AVAILABLE LICENSES:**

- Single User License \$4650.00
- 2-5 Users License \$5580.00
- Site License \$6696.00
- Enterprise License \$8035.00

### **Report description:**

#### Description

#### Report Scope

This report analyzes the global market for cell and gene therapy tools and reagents. The market is segmented by product type, disease or application, end user and region. Product types include gene vectors, GMP proteins, GMP antibodies, GMP small molecules, bioreactors, multiplex immunoassays, immunoassays, leukapheresis, cell separation, cell expansion, cytokine release syndrome monitoring, cryopreservation reagents, and solutions and media. Diseases or applications include cancer and rare diseases. End users include pharmaceutical and biotech companies, academic research institutes, and clinical laboratories. The regions covered are North America, Europe, Asia-Pacific and the Rest of the World (RoW). For market estimates, data has been provided for 2023 as the base year, with forecasts for 2024 through 2029.

This report also examines strategies and collaborations, discusses the regulatory landscape, and analyzes macroeconomic factors when considering new technologies, the industry's increasing competitiveness, and emerging customer needs. This report also examines analytical frameworks, such as ESG analysis, patent analysis, competitive analysis, and strategic recommendations, which will aid companies in devising their strategic plans.

#### Report Includes

- 44 data tables and 57 additional tables
- An update on the global market for cell and gene therapy tools and reagents
- Analyses of the global market trends, with historic market revenue for 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029
- A look at the market potential for the cell and gene therapy tools and reagents in the life sciences industry, market drivers, and forecasts for the market segments of product, application, end user and region
- Facts and figures pertaining to major market dynamics, product innovations, clinical trials, and government regulations
- Review of the prevalence of infectious disease, metabolic disorders and chronic ailments, along with the recent technological advances, competitive landscape, and the industry value chain

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- Coverage of the technological, economic and business considerations of the market, and the vendor landscape
- Analysis of the industry's regulatory framework and policies, and product pipeline
- Discussion of ESG challenges and ESG practices in the industry
- Market share analysis of the key companies in the industry and coverage of their proprietary technologies and strategies
- Company profiles of major players within the industry, including Thermo Fisher Scientific Inc., Sartorius CellGenix GmbH, and Miltenyi Biotec

## Executive Summary

### Summary:

Cell and gene therapy (CGT) is emerging as an essential tool for safeguarding human health. Techniques such as chimeric antigen receptor T-cell (CAR-T) therapy have emerged as ways to treat many cancers. The promise of gene therapy using technologies such as clustered regularly interspaced short palindromic repeats (CRISPR) is being realized in clinical trials. Therapies are being scaled up to treat life-threatening diseases. The global CDMO market was valued at \$128 billion in 2023. The market is expected to grow at a compound annual growth rate (CAGR) of 7.0% to reach approximately \$191.6 billion by the end of 2029.

The CDMO sector is dynamic and offers service providers a wealth of opportunities for expansion. As the CDMO sector is trending toward consolidation, CDMO businesses are shifting focus to become one-stop shops or integrated pharmaceutical service providers.

With comprehensive services covering the whole drug development and manufacturing process, CDMOs are essential to the pharmaceutical industry. What distinguishes CDMOs from other service providers is this end-to-end support. A CDMO can offer services like pre-formulation and formulation development in the early phases of drug development. After the drug formulation is created, the CDMO can help with stability testing as well. A CDMO can supply clinical trial materials once the drug enters the clinical trial stage. These materials consist of the investigational medicinal product (IMP) that will be given to patients throughout the study and the paperwork required to comply with regulatory requirements. Ultimately, a CDMO can increase production from clinical trial quantities to commercial-scale quantities after the drug is approved for marketing. They can also manage the final product's packaging and delivery.

- Thermo Fisher Scientific Inc.

diseases such as cancer and rare gene-based diseases. As these therapies come to the fore, a new market for tools to develop these therapies using standard methodologies is emerging. CGT uses cells and genetic material to fight diseases. Cell therapy involves the transplantation of healthy human cells into a patient's body to replace or repair diseased or damaged tissue or cells. Gene therapy modifies a patient's genetic material. These are overlapping fields. Some products are developed using both cell and gene therapies. Tools and reagents are required to develop cell and gene therapies.

### Table of Contents:

Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Chapter 2 Market Overview
Overview

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Technology Background: Cell Therapy  
Types of Cell Therapy  
Technology Background: Gene Therapy  
Types of Gene Therapy  
Approved CGT Products  
Chapter 3 Market Dynamics  
Market Dynamics  
Market Drivers  
Investments in CGT Research  
Capacity Expansions for Clinical and Commercial Manufacturing  
Increasing Incidence of Chronic Diseases  
Collaborations and Acquisitions  
Market Restraints  
Complexity in Manufacturing and Supply Chain  
Lack of Skilled Force  
Market Opportunities  
Harnessing the Advances in CGT Technologies  
Regulatory Landscape  
Gene Therapy Regulations  
Cell Therapy Regulations  
Viral and Non-Viral Vectors  
Media  
GMP Proteins and Antibodies  
Leukapheresis  
CGT Regulations in Europe  
Chapter 4 Emerging Technologies and Developments  
Closed and Automated Systems  
Single-Use Technologies  
Chapter 5 Market Segmentation Analysis  
Market Trends  
Segmentation Breakdown  
Global Market for CGT Tools and Reagents, by Product  
Immunoassays  
Bioreactors  
Leukapheresis  
GMP Antibodies  
Multiplex Immunoassays  
Vectors  
Cell Separation  
Cryopreservation  
Cell Expansion  
Media  
GMP Proteins  
GMP Small Molecules  
CRS Monitoring  
Global Market for CGT Tools and Reagents, by Application  
Cancer

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Rare Diseases  
Other Diseases  
Global Market for CGT Tools and Reagents, by End User  
Pharmaceutical and Biotech Companies  
Academic and Research Institutes  
Clinical Laboratories  
Geographic Breakdown  
Global Market for CGT Tools and Reagents, by Region  
North America  
Europe  
Asia-Pacific  
Rest of the World  
Chapter 6 Competitive Intelligence  
Ranking of Leading Players  
Strategies of Leading Companies  
Product Launches  
Collaborations and Partnerships  
Expansions  
Agreements  
Acquisitions  
Others  
Chapter 7 Sustainability in the CGT Tool and Reagent Market: ESG Perspective  
Introduction to ESG  
ESG Performance in the Industry  
ESG Practices in the CGT Tool and Reagent Industry  
Environmental Performance  
Concluding Remarks from BCC Research  
Chapter 8 Appendix  
Methodology  
Abbreviations  
References  
Company Profiles  
ABCAM LTD.  
ADVERUM BIOTECHNOLOGIES INC.  
AKRON BIOTECH  
BIO-RAD LABORATORIES INC.  
BIO-TECHNE  
CYTIVA  
FUJIFILM IRVINE SCIENTIFIC  
MILTENYI BIOTEC  
PROTEINTECH GROUP INC.  
QIAGEN  
REVVITY  
SARTORIUS CELLGENIX GMBH  
STEMCELL TECHNOLOGIES  
THERMO FISHER SCIENTIFIC INC.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

## Cell and Gene Therapy Tools, and Reagents: Global Markets

Market Research Report | 2024-11-07 | 136 pages | BCC Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

### ORDER FORM:

Select license	License	Price
	Single User License	\$4650.00
	2-5 Users License	\$5580.00
	Site License	\$6696.00
	Enterprise License	\$8035.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-06-25"/>
		Signature	

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)  
[www.scotts-international.com](http://www.scotts-international.com)